/BLUE

BLUE Stock - bluebird bio, Inc.

Q: What is the analyst price target for BLUE?

Analyst price target information is not currently available for BLUE.

Q: What is BLUE's market cap?

Market capitalization information is not currently available for BLUE.

Healthcare|Biotechnology|NASDAQ

$4.97+0.00%

+$0.00 (+0.00%) • Jun 2

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+175.5%upside

Target: $13.69

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BLUE

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.36

52W High$28.60

52W Low$3.20

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$83.81M	$29.50M	$3.60M	$3.66M	$250.73M
Gross Profit	$-5,573,000	$-4,030,000	$-6,480,000	$-35,195,000	$245.34M
Gross Margin	-6.6%	-13.7%	-180.2%	-961.1%	97.8%
Operating Income	$-270,461,000	$-244,262,000	$-250,185,000	$-590,911,000	$-559,259,000
Net Income	$-240,715,000	$-211,913,000	$-230,342,000	$-819,378,000	$-618,695,000
Net Margin	-287.2%	-718.4%	-6403.7%	-22375.2%	-246.8%
EPS	$-24.84	$-2.97	$-3.39	$-8.16	$-9.95

Company Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

40%

Hold / Neutral

60%

Sell / Underperform

Analyst Consensus🔴 Bearish

4 Bullish6 Neutral/Bearish

Price Targets

Average Target

↑ 37.6% Upside

Now

Low

Average

$10

High

Based on 8 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
February 24th 2025	JP Morgan	Upgrade	Neutral	-
November 15th 2024	JP Morgan	Downgrade	Underweight	-
November 15th 2024	BofA Securities	Downgrade	Neutral	$0.5← $3
August 15th 2024	JP Morgan	Downgrade	Neutral	-
December 11th 2023	HSBC Securities	Downgrade	Reduce	-
December 8th 2023	Morgan Stanley	Upgrade	Equal Weight	$7← $3
October 17th 2023	Cantor Fitzgerald	Initiation	Neutral	-
September 6th 2023	HSBC Securities	Initiation	Buy	$4.21
July 19th 2023	BofA Securities	Upgrade	Buy	$10← $6
June 1st 2023	Barclays	Upgrade	Overweight	$8← $7
April 28th 2023	JP Morgan	Initiation	Overweight	$7
March 7th 2023	Robert W. Baird	Initiation	Outperform	$10
August 5th 2022	Barclays	Upgrade	Equal Weight	-
August 2nd 2022	Raymond James	Upgrade	Outperform	$8
April 6th 2022	Cowen	Downgrade	Market Perform	-

Earnings History & Surprises

BLUE

Beat Rate

53%

Last 17 quarters

Avg Surprise

-227.5%

EPS vs Estimate

Beats / Misses

9/7

1 met exactly

Latest EPS

$-2.66

Q2 2025

EPS Surprise History

Q3 23

+6.9%

$-13.40vs$-14.40

Q4 23

+4.3%

$-13.20vs$-13.80

Q1 24

-13.1%

$-0.75vs$-0.66

Q2 24

+142.9%

$0.21vs$-0.49

Q3 24

-3800.0%

$-15.60vs$-0.40

Q4 24

+14.8%

$-6.20vs$-7.28

Q1 25

-559.4%

$-23.74vs$-3.60

Q2 25

+32.5%

$-2.66vs$-3.94

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 12, 2026	—	—	—	—
Q4 2025	Nov 12, 2025	—	—	—	—
Q3 2025	Aug 12, 2025	$-1.91	—	—	—
Q2 2025	May 14, 2025	$-3.94	$-2.66	+32.5%	✓ BEAT
Q1 2025	Mar 27, 2025	$-3.60	$-23.74	-559.4%	✗ MISS
Q4 2024	Nov 14, 2024	$-7.28	$-6.20	+14.8%	✓ BEAT
Q3 2024	Sep 13, 2024	$-0.40	$-15.60	-3800.0%	✗ MISS
Q2 2024	May 9, 2024	$-0.49	$0.21	+142.9%	✓ BEAT
Q1 2024	Mar 26, 2024	$-0.66	$-0.75	-13.1%	✗ MISS
Q4 2023	Nov 7, 2023	$-13.80	$-13.20	+4.3%	✓ BEAT
Q3 2023	Aug 8, 2023	$-14.40	$-13.40	+6.9%	✓ BEAT
Q2 2023	May 9, 2023	$-10.80	$4.20	+138.9%	✓ BEAT
Q1 2023	Mar 29, 2023	$-9.00	$7.60	+184.4%	✓ BEAT
Q4 2022	Nov 7, 2022	$-25.60	$-18.40	+28.1%	✓ BEAT
Q3 2022	Aug 4, 2022	$-26.20	$-25.80	+1.5%	✓ BEAT
Q2 2022	May 9, 2022	$-25.20	$-33.20	-31.7%	✗ MISS
Q1 2022	Mar 4, 2022	$-36.40	$-36.40	0.0%	= MET
Q4 2021	Nov 5, 2021	$-54.40	$-58.60	-7.7%	✗ MISS
Q3 2021	Aug 9, 2021	$-65.20	$-71.60	-9.8%	✗ MISS
Q2 2021	May 5, 2021	$-61.00	$-61.40	-0.7%	✗ MISS